Recombinant Human Pappalysin-2 (PAPPA2), partial

1. PAPP-A2 mutation is associated with idiopathic short stature. PMID:29653372
2. The findings suggest a possible pathophysiological link between the development of Fetal growth restriction and the expression of PAPPA, PAPPA2 and PLAC-1. PMID:29532882
3. Pregnancy associated plasma protein-A (PAPP-A) appears to be a potentially useful biomarker for short-term risk stratification of patients presenting with chest pain of ischemic origin (Review). PMID:29144175
4. PAPP-A2 is increased in Hemodialysis patients and interacts with PAPP-A on patients prognosis. PMID:28854436
5. This review evaluates the current data concerning PAPP-A2 function, and particularly the effect of PAPP-A2 mutation on growth. PMID:29238946
6. These patients provide important insights into the regulation of longitudinal growth in humans, documenting the critical role of PAPP-A2 in releasing IGF-I from its binding proteins. PMID:26902202
7. Short-term treatment with progressive doses of rhIGF1 (recombinant human insulin-like growth factor-1) improved growth in two siblings with deficiency of PAPP-A2 (pregnancy-associated plasma protein-A2) [due to a homozygous loss-of-function frameshift mutation in exon 3 of the PAPP-A2 gene (p.D643fs25*)] that resulted in postnatal growth failure due to resulting decrease in IGF1 bioavailability. [CASE REPORT] PMID:27648969
8. in situ hybridization (ISH) and immunohistochemistry (IHC) were employed to examine the spatial and temporal expression of PAPPA2 in the human fetomaternal interface. PMID:27525857
9. PAPP-A2 is differentially expressed in different trophoblast populations and shows strong down regulation in the mid second trimester in chorionic villous samples. PMID:26748159
10. overexpression in Down syndrome from placental mRNA to maternal serum protein PMID:25154785
11. The association between this PAPPA2 single nucleotide polymorphism and developmental dysplasia of the hip was evaluated. PMID:24672801
12. The upregulation of PAPP-A2 observed in preeclampsia at term occurs early in pregnancy, before the symptoms develop. PMID:24336677
13. PAPPA2 may be upregulated in severe pre-eclampsia and, functionally, this may be mediated via increased placental hypoxia known to occur with this pregnancy disorder. PMID:23484525
14. The existence of this assay will enable an assessment of the biomarker potential of PAPP-A2 in pre-eclampsia as well as other clinical conditions. PMID:23804707
15. Association of a single nucleotide polymorphism in pregnancy-associated plasma protein-A2 with developmental dysplasia of the hip PMID:22037112
16. factors previously known to be highly expressed in preeclamptic placentae (PGE2 and TNF-alpha), contribute to the upregulation of PAPPA2. results are consistent with the hypothesis that PAPPA2 is upregulated as a consequence of placental pathology PMID:21496272
17. Circulating IGFBP-5 is proteolyzed by PAPP-A2 during pregnancy, resulting in increased IGF bioavailability, which may have important consequences for the development of the fetus and/or the well-being of the mother. PMID:20103653
18. Seven placental transcripts characterize HELLP-syndrome. PMID:18374411
19. PAPP-A2 in syncytiotrophoblast cells was dramatically increased in pre-eclampsia. Maternal serum concentrations of PAPP-A2 were also significantly elevated in pre-eclampsia as compared with uncomplicated pregnancy. PMID:18805800
20. Preeclampsia involves changes in the gene expression of PAPPA2 in placental cytotrophoblasts. PMID:18818296
21. PAPPA2 is expressed in the syncytiotrophoblast layer of human placental villi and is also detected in some invasive extravillous trophoblasts in the first trimester PMID:19474058

Show More

Hide All

HGNC: 14615

UNIGENE: Hs.187284

KEGG: hsa:60676

STRING: 9606.ENSP00000356634